Regulatory professionals out of spotlight and not understood, but "highly valued"
This article was originally published in SRA
Regulatory professionals in the healthcare products sector consider themselves to be highly valued by their employers, even though they say their work is not fully understood. Many outside the regulatory community have never heard of the profession and have little understanding of the regulatory process surrounding healthcare products1.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.
2020 is not getting off to a good start for manufacturers needing to comply with the EU’s new Medical Device Regulation on 26 May 2020. The European Commission’s latest document seems to confirm industry’s fears about the ability of the EU’s medtech system to be ready in time.